Ongoing clinical trials targeting PD‐1, NKG2A (e.g., monalizumab), and KIRs (e.g., IPH2101), alone or in combination, show encouraging efficacy across tumor types (clinicaltrials.gov) [52–55]. This evidence concerns the gene KLRC1 and neoplasm.